NeilAroninMD

Diabetes, Lipid Metabolism, Pituitary Disorders & Neuroendocrinology

Professor of Medicine, University Mass School of Medicine

Dr. Aronin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
55 Lake Ave N
Department Of Endocrinology
Worcester, MA 01655
Phone+1 508-856-3536

Brigham and Women's Hospital/Massachusetts General Hospital/Harvard Medical SchoolResidency, Neurology, 1979 - 1982
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1978 - 1979
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1977 - 1978
Duke University HospitalResidency, Internal Medicine, 1974 - 1977
Perelman School of Medicine at the University of PennsylvaniaClass of 1974

Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011
Fellow (FACE) American Association of Clinical Endocrinology

PubMed

192 citations
Five siRNAs targeting three SNPs may provide therapy for three-quarters of Huntington's disease patients.
Edith L. Pfister, Lori A. Kennington, Juerg R. Straubhaar, Sujata Wagh, Wanzhou Liu
Current Biology. 2009-05-12
6 citations
Allele-specific knockdown of mutant HTT protein via editing at coding region SNP heterozygosities.
Sarah R. Oikemus, Edith L. Pfister, Ellen Sapp, Kathryn Chase, Lori A. Kennington
Human Gene Therapy. 2021-08-10
14 citations
Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington's disease models.
Faith Conroy, Rachael Miller, Julia F Alterman, Matthew R Hassler, Dimas Echeverria
Nature Communications. 2022-10-03

Journal Articles

A Fresh Look at Huntingtin mRNA Processing in Huntington’s Disease
Neil Aronin, MD, Journal of Pediatric Rehabilitation Medicine

Atalanta Therapeutics Strengthens Leadership Team with Key Appointments in R&D and Corporate DevelopmentOctober 7th, 2021
Atalanta Therapeutics Launches to Develop RNAi Therapies for Neurodegenerative DiseasesJanuary 14th, 2021
RNAi Biotech Atalanta Debuts with $110m plus Biogen and Roche CNS Tie-UpsJanuary 12th, 2021
Join now to see all

Signaling Mechanisms In Neuronal DegenerationNational Institute Of Neurological Disorders And Stroke1999–2012
Interdisciplinary Studies In Hormone FunctionNational Institute Of Diabetes And Digestive And Kidney Diseases2008–2011
Receptor Mechanisms In Movement Disorder PathophysiologyNational Institute Of Neurological Disorders And Stroke1996–1998
Hypothalamic Anterior Pituitary RelationshipsNational Institute Of Diabetes And Digestive And Kidney Diseases1986
Hypothalamic Anterior Pituitary RelationshipsNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985